top of page
The Professional Network for Healthcare Experts
FDA approves Onswik as once-weekly basal insulin for adults with type 2 diabetes
The FDA has approved Lilly's Onswik as a once-weekly basal insulin for adults with type 2 diabetes, reducing the frequency of basal insulin injections from daily to weekly dosing.
nuaxia
Sep 252 min read
Mankind Pharma licenses insulin degludec and insulin degludec–aspart combination for India
The exclusive agreement expands Mankind Pharma's injectable diabetes portfolio with two long-acting insulin analogues while strengthening its strategy of in-licensing innovative therapies for the Indian market.
nuaxia
Aug 212 min read
bottom of page